MetaCap

Zura Bio Limited Class A (ZURA)

NASDAQ: ZURAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

0.9305-0.0219 (-2.30%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ZURA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$89.63M
EPS (TTM)
-$1.11
52-week range
0.919 – 7.44
Day range
0.9192 – 1.00
Volume / Avg
4.76M / 4.47M
Beta
—

52-week range

$0.919$7.44

ZURA stock today

Shares of Zura Bio (ZURA) finished lower on Nov 20 at $0.9305, a drop of 2.30% or $0.0219 per share, versus the S&P 500's 3.70% decline. At this level, ZURA sits near the bottom of its 52-week range of $0.919 to $7.44: 87.5% below the high, set on Mar 10, 2026 and 1.3% above the low. ZURA is down 82.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 74.4%.

Zura Bio has posted a net loss over the last twelve months (EPS of -$1.11), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Zura Bio

Company profile

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Sandeep Chidambar Kulkarni M.D.
Headquarters
Henderson, NV
Employees
40

Financial highlights

Full financials

Zura Bio reported a net loss of $68.7 million, compared with a loss of $52.4 million a year earlier. Diluted earnings per share came in at -$1.06.

Zura Bio annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022
Revenue————
Growth————
Net income$-68.65M$-52.40M$-60.36M$-25.70M
EPS (diluted)$-1.06$-0.60$-2.09—

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$8.00+759.75%

  • Strong buy 1
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $12.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.20 vs $-0.22
Surprise
+9.09%

ZURA news

All ZURA news

Zura Bio peers

Health Care sector
ZURA peer companies
CompanyPrice% ChgMarket capCompare
LENZLENZ Therapeutics Inc.2.97-11.23%$93.16Mvs ZURA
OTLKOutlook Therapeutics Inc.0.39-2.74%$94.94Mvs ZURA
VYGRVoyager Therapeutics Inc.1.53-4.97%$95.21Mvs ZURA
IPHAInnate Pharma S.A. ADS0.8634-8.14%$96.44Mvs ZURA
MOLNMolecular Partners AG ADR2.53-5.25%$96.80Mvs ZURA
BDTXBlack Diamond Therapeutics Inc.1.31-5.76%$75.28Mvs ZURA
CRDLCardiol Therapeutics Inc. Class A0.8626-2.28%$110.14Mvs ZURA
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs ZURA

Indexes, lists and sector

Zura Bio stock FAQ

What is Zura Bio's stock price today?

ZURA last traded at $0.9305 as of Nov 20, 4:00 PM EST, down 2.30% on the day. Prices are delayed at least 15 minutes.

Who is Zura Bio's CEO?

Dr. Sandeep Chidambar Kulkarni M.D. is the chief executive officer of Zura Bio Limited Class A, which has about 40 employees.

What is the ZURA 52-week high?

The 52-week high for ZURA is $7.44 and the 52-week low is $0.919. The stock is currently 87.5% below its high.

Compare ZURA